We are international

Sydney 2005: Lack of Mcl-1 Confers Resistance to Bortezomib and Melphalan but not Doxorubicin
By Steven Le Gouill
Dr. Le Gouill concluded the final focus session with a discussion on bortezomib and Mcl-1. As mentioned throughout this session, resistance to novel agents, such as bortezomib, is unknown. Mcl-1 is an antiapoptotic protein that protects MM cells against spontaneous and dexamethasone-induced apoptosis. His study investigated the role of Mcl-1 in bortezomib-induced apoptosis in comparison to conventional therapies doxorubicin and melphalan. His analyses suggest that bortezomib and melphalan, but not doxorubicin, triggers Mcl-1-dependent-induced apoptosis pathways. His study demonstrates that Mcl-1 may be an important mediator of bortezomib and melphalan-induced apoptosis.

Back to session summary

 related articles